Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (1066)	6/21/1999 7:09:00 PM
From: P.M.Freedman	Respond to of 1686

Harold--As a trader, I am not only looking for volatility but also trends. If a company has more potentiality to grow, I will adjust my long/short ratios to meet the trend. That's why I would like to discuss with others for the companies I am interested in, no matter positive or negative comments. Actually my l/s ratio in Biogen is pretty high historically. I personally believe BGEN is currently overvalued in comparison with some of high profile biotechs. I am also a long term holder of some other stocks as you are being in BGEN. Someone does not like to hear an opinion that is against his/her position. It is, for sure, no good for him/her to get better understanding on what kind of a company he/she is investing in. Your postings in this thread are pretty valuable. So please keep doing so. Good luck!

To: Harold Engstrom who wrote (1066)	6/22/1999 9:24:00 PM
From: PuddleGlum	Respond to of 1686

Harold- Since this thread seems to have a number of scientist-types on it I thought I'd offer a url of considerable interest to beginning biotechies: brunel.ac.uk It even points you in the right direction to be able to run BLAST, if you happen to have any DNA sequences that you want info on. pg

To: Harold Engstrom who wrote (1066)	6/23/1999 10:40:00 AM
From: Beltropolis Boy	Read Replies (1) \| Respond to of 1686

Biogen Receives Clearance to Build New R&D Facility in Cambridge June 23, 1999 09:19 AM CAMBRIDGE, Mass., June 23 /PRNewswire/ -- Biogen, Inc. (BGEN) today announced that the Cambridge Planning Board has granted the Company's IPOP (Interim Planning Overlay Permit) application to construct a 210,000 square foot building intended for research and development office use. Biogen's IPOP application is the first such petition to be granted by the Cambridge Planning Board. The new six-story building will be located at 15 Cambridge Center and will accommodate approximately 400 new employees. Jim Vincent, Biogen's Chairman and Chief Executive Officer, said, "Biogen's planned construction of a new building in Cambridge Center is indicative of the Company's rapid growth and of its commitment to expand its presence in the city of Cambridge." Founded in 1978, Biogen currently employs 1,200 people worldwide, 800 of whom are located in the Company's five existing Cambridge Center facilities. The company also maintains a manufacturing plant in Research Triangle Park, North Carolina, and country offices in Canada, France, the United Kingdom, Germany, and The Netherlands.